Skip to main content
NCBI home page
Journal of Psychiatry & Neuroscience : JPN logoLink to Journal of Psychiatry & Neuroscience : JPN
. 1995 Jul;20(4):297–304.

Melatonin responses to clonidine and yohimbine challenges.

S H Kennedy 1, W Gnam 1, E Ralevski 1, G M Brown 1
PMCID: PMC1188705  PMID: 7647083

Abstract

Melatonin (MT) release from the pineal gland has been used as a marker for central noradrenergic function in major depression. Norepinephrine acts at both alpha and beta adrenergic receptors on the pinealocyte membrane to mediate nocturnal MT release, but in humans the contribution of each receptor class is unclear. In order to explore the effect of alpha 2 receptors on MT release, 10 female subjects were given oral challenges, in separate placebo-controlled trials, of either 10.8 mg of yohimbine, an alpha 2 adrenergic antagonist, or clonidine, a partial alpha 2 adrenergic agonist, at doses of either 200 micrograms or 300 micrograms. Post-challenge serum melatonin was measured from 18:00 h to 22:00 h in both studies as was urinary 6-sulphatoxy-melatonin (aMT6s), the major metabolite of MT (from 18:00 h to 22:00 h, and from 22:00 h to 10:00 h). Growth hormone (GH) was also assayed following the clonidine challenge, and blood pressure, pulse rate, and side effects were monitored after both challenges. Neither yohimbine nor clonidine significantly altered nocturnal serum MT levels compared to placebo. However, there was a significant increase in urinary aMT6s between 18:00 h and 22:00 h following yohimbine ingestion. Yohimbine ingestion produced significant rises in pulse rate and the urge to urinate compared to placebo. Both doses of clonidine resulted in a significant reduction in pulse rate, systolic and diastolic blood pressure, and significant increases in drowsiness and other measures of sedation following ingestion. Only clonidine 300 micrograms produced a significant elevation in GH release. This study highlights the limitations of oral neuroendocrine challenge studies.

Full text

PDF
297

Images in this article

300Figure 2
on p.300

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aldhous M. E., Arendt J. Radioimmunoassay for 6-sulphatoxymelatonin in urine using an iodinated tracer. Ann Clin Biochem. 1988 May;25(Pt 3):298–303. doi: 10.1177/000456328802500319. [DOI] [PubMed] [Google Scholar]
  2. Bowers C. W., Zigmond R. E. The influence of the frequency and pattern of sympathetic nerve activity on serotonin N-acetyltransferase in the rat pineal gland. J Physiol. 1982 Sep;330:279–296. doi: 10.1113/jphysiol.1982.sp014341. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Brismar K., Hylander B., Eliasson K., Rössner S., Wetterberg L. Melatonin secretion related to side-effects of beta-blockers from the central nervous system. Acta Med Scand. 1988;223(6):525–530. doi: 10.1111/j.0954-6820.1988.tb17690.x. [DOI] [PubMed] [Google Scholar]
  4. Brown G. M., Mazurek M., Allen D., Szechtman B., Cleghorn J. M. Dose-response profiles of plasma growth hormone and vasopressin after clonidine challenge in man. Psychiatry Res. 1990 Mar;31(3):311–320. doi: 10.1016/0165-1781(90)90100-j. [DOI] [PubMed] [Google Scholar]
  5. Brown M. J., Harland D. Evidence for a peripheral component in the sympatholytic effect of clonidine in rats. Br J Pharmacol. 1984 Nov;83(3):657–665. doi: 10.1111/j.1476-5381.1984.tb16219.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Charney D. S., Heninger G. R. Abnormal regulation of noradrenergic function in panic disorders. Effects of clonidine in healthy subjects and patients with agoraphobia and panic disorder. Arch Gen Psychiatry. 1986 Nov;43(11):1042–1054. doi: 10.1001/archpsyc.1986.01800110028005. [DOI] [PubMed] [Google Scholar]
  7. Charney D. S., Heninger G. R., Breier A. Noradrenergic function in panic anxiety. Effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder. Arch Gen Psychiatry. 1984 Aug;41(8):751–763. doi: 10.1001/archpsyc.1984.01790190025003. [DOI] [PubMed] [Google Scholar]
  8. Cowen P. J., Fraser S., Sammons R., Green A. R. Atenolol reduces plasma melatonin concentration in man. Br J Clin Pharmacol. 1983 May;15(5):579–581. doi: 10.1111/j.1365-2125.1983.tb02099.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. De Sarro G. B., Ascioti C., Froio F., Libri V., Nisticò G. Evidence that locus coeruleus is the site where clonidine and drugs acting at alpha 1- and alpha 2-adrenoceptors affect sleep and arousal mechanisms. Br J Pharmacol. 1987 Apr;90(4):675–685. doi: 10.1111/j.1476-5381.1987.tb11220.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Fellenberg A. J., Phillipou G., Seamark R. F. Urinary 6-sulphatoxy melatonin excretion during the human menstural cycle. Clin Endocrinol (Oxf) 1982 Jul 1;17(1):71–75. doi: 10.1111/j.1365-2265.1982.tb02635.x. [DOI] [PubMed] [Google Scholar]
  11. Frankhuijzen A. L., Wardeh G., Hogenboom F., Mulder A. H. Alpha 2-adrenoceptor mediated inhibition of the release of radiolabelled 5-hydroxytryptamine and noradrenaline from slices of the dorsal region of the rat brain. Naunyn Schmiedebergs Arch Pharmacol. 1988 Mar;337(3):255–260. doi: 10.1007/BF00168835. [DOI] [PubMed] [Google Scholar]
  12. Glue P., Wilson S., Campling G. M., Knightly M., Franklin M., Cowen P. J., Nutt D. J. Alpha-2-adrenoceptor control of cortisol and ACTH in normal volunteers: preliminary open trial of the effects of acute and chronic idazoxan. Psychoneuroendocrinology. 1992 May-Jul;17(2-3):261–266. doi: 10.1016/0306-4530(92)90066-g. [DOI] [PubMed] [Google Scholar]
  13. Golden R. N., Markey S. P., Risby E. D., Rudorfer M. V., Cowdry R. W., Potter W. Z. Antidepressants reduce whole-body norepinephrine turnover while enhancing 6-hydroxymelatonin output. Arch Gen Psychiatry. 1988 Feb;45(2):150–154. doi: 10.1001/archpsyc.1988.01800260060008. [DOI] [PubMed] [Google Scholar]
  14. Grasby P. M., Begg E. J., Gartside S. E., Cowen P. J. Effect of idazoxan on evening melatonin plasma concentrations in healthy volunteers. Biol Psychiatry. 1989 Aug;26(4):412–416. doi: 10.1016/0006-3223(89)90058-9. [DOI] [PubMed] [Google Scholar]
  15. Guthrie S. K., Grunhaus L., Pande A. C., Hariharan M. Noradrenergic response to intravenous yohimbine in patients with depression and comorbidity of depression and panic. Biol Psychiatry. 1993 Oct 15;34(8):558–561. doi: 10.1016/0006-3223(93)90199-n. [DOI] [PubMed] [Google Scholar]
  16. HOLMBERG G., GERSHON S. Autonomic and psychic effects of yohimbine hydrochloride. Psychopharmacologia. 1961;2:93–106. doi: 10.1007/BF00592678. [DOI] [PubMed] [Google Scholar]
  17. Kennedy S. H., Brown G. M. Effect of chronic antidepressant treatment with adinazolam and desipramine on melatonin output. Psychiatry Res. 1992 Aug;43(2):177–185. doi: 10.1016/0165-1781(92)90132-m. [DOI] [PubMed] [Google Scholar]
  18. Lewy A. J., Siever L. J., Uhde T. W., Markey S. P. Clonidine reduces plasma melatonin levels. J Pharm Pharmacol. 1986 Jul;38(7):555–556. doi: 10.1111/j.2042-7158.1986.tb04639.x. [DOI] [PubMed] [Google Scholar]
  19. Marwaha J., Aghajanian G. K. Relative potencies of alpha-1 and alpha-2 antagonists in the locus ceruleus, dorsal raphe and dorsal lateral geniculate nuclei: an electrophysiological study. J Pharmacol Exp Ther. 1982 Aug;222(2):287–293. [PubMed] [Google Scholar]
  20. Moore D. C., Paunier L., Sizonenko P. C. Effect of adrenergic stimulation and blockade on melatonin secretion in the human. Prog Brain Res. 1979;52:517–521. doi: 10.1016/S0079-6123(08)62959-3. [DOI] [PubMed] [Google Scholar]
  21. Murburg M. M., Villacres E. C., Ko G. N., Veith R. C. Effects of yohimbine on human sympathetic nervous system function. J Clin Endocrinol Metab. 1991 Oct;73(4):861–865. doi: 10.1210/jcem-73-4-861. [DOI] [PubMed] [Google Scholar]
  22. Nutt D. J. Altered central alpha 2-adrenoceptor sensitivity in panic disorder. Arch Gen Psychiatry. 1989 Feb;46(2):165–169. doi: 10.1001/archpsyc.1989.01810020067011. [DOI] [PubMed] [Google Scholar]
  23. Palazidou E., Papadopoulos A., Ratcliff H., Dawling S., Checkley S. A. Noradrenaline uptake inhibition increases melatonin secretion, a measure of noradrenergic neurotransmission, in depressed patients. Psychol Med. 1992 May;22(2):309–315. doi: 10.1017/s0033291700030257. [DOI] [PubMed] [Google Scholar]
  24. Palazidou E., Papadopoulos A., Sitsen A., Stahl S., Checkley S. An alpha 2 adrenoceptor antagonist, Org 3770, enhances nocturnal melatonin secretion in man. Psychopharmacology (Berl) 1989;97(1):115–117. doi: 10.1007/BF00443424. [DOI] [PubMed] [Google Scholar]
  25. Price L. H., Charney D. S., Rubin A. L., Heninger G. R. Alpha 2-adrenergic receptor function in depression. The cortisol response to yohimbine. Arch Gen Psychiatry. 1986 Sep;43(9):849–858. doi: 10.1001/archpsyc.1986.01800090035006. [DOI] [PubMed] [Google Scholar]
  26. Raskind M. A., Peskind E. R., Veith R. C., Beard J. C., Gumbrecht G., Halter J. B. Increased plasma and cerebrospinal fluid norepinephrine in older men: differential suppression by clonidine. J Clin Endocrinol Metab. 1988 Feb;66(2):438–443. doi: 10.1210/jcem-66-2-438. [DOI] [PubMed] [Google Scholar]
  27. Rasmussen S. A., Goodman W. K., Woods S. W., Heninger G. R., Charney D. S. Effects of yohimbine in obsessive compulsive disorder. Psychopharmacology (Berl) 1987;93(3):308–313. doi: 10.1007/BF00187248. [DOI] [PubMed] [Google Scholar]
  28. Rubin R. T., Heist E. K., McGeoy S. S., Hanada K., Lesser I. M. Neuroendocrine aspects of primary endogenous depression. XI. Serum melatonin measures in patients and matched control subjects. Arch Gen Psychiatry. 1992 Jul;49(7):558–567. doi: 10.1001/archpsyc.1992.01820070052008. [DOI] [PubMed] [Google Scholar]
  29. Siever L. J., Uhde T. W. New studies and perspectives on the noradrenergic receptor system in depression: effects of the alpha 2-adrenergic agonist clonidine. Biol Psychiatry. 1984 Feb;19(2):131–156. [PubMed] [Google Scholar]
  30. Svensson T. H., Usdin T. Feedback inhibition of brain noradrenaline neurons by tricyclic antidepressants: alpha-receptor mediation. Science. 1978 Dec 8;202(4372):1089–1091. doi: 10.1126/science.213833. [DOI] [PubMed] [Google Scholar]
  31. Tulen J. H., van de Wetering B. J., Kruijk M. P., von Saher R. A., Moleman P., Boomsma F., van Steenis H. G., Man in 't Veld A. J. Cardiovascular, neuroendocrine, and sedative responses to four graded doses of clonidine in a placebo-controlled study. Biol Psychiatry. 1992 Sep 15;32(6):485–500. doi: 10.1016/0006-3223(92)90217-n. [DOI] [PubMed] [Google Scholar]
  32. Vaughan G. M., Pelham R. W., Pang S. F., Loughlin L. L., Wilson K. M., Sandock K. L., Vaughan M. K., Koslow S. H., Reiter R. J. Nocturnal elevation of plasma melatonin and urinary 5-hydroxyindoleacetic acid in young men: attempts at modification by brief changes in environmental lighting and sleep and by autonomic drugs. J Clin Endocrinol Metab. 1976 Apr;42(4):752–764. doi: 10.1210/jcem-42-4-752. [DOI] [PubMed] [Google Scholar]
  33. Wetterberg L., Arendt J., Paunier L., Sizonenko P. C., Donselaar W., Heyden T. Human serum melatonin changes during the menstrual cycle. J Clin Endocrinol Metab. 1976 Jan;42(1):185–188. doi: 10.1210/jcem-42-1-185. [DOI] [PubMed] [Google Scholar]
  34. Zandberg P., De Jong W., De Wied D. Effect of catecholamine-receptor stimulating agents on blood pressure after local application in the nucleus tractus solitarii of the medulla oblongata. Eur J Pharmacol. 1979 Apr 1;55(1):43–56. doi: 10.1016/0014-2999(79)90146-8. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Psychiatry and Neuroscience are provided here courtesy of Canadian Science Publishing

RESOURCES